Patents by Inventor Ronnie C. Mease

Ronnie C. Mease has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20190023722
    Abstract: PSMA-targeted PET/SPECT agents for imaging PSMA-positive cancer and or tumor neovasculature and PSMA-targeted radiotherapeutic agent for the treatment of PSMA-positive cancer or tumor neovasculature are disclosed. Methods of imaging PSMA expressing tumors, or cells and kits also are disclosed.
    Type: Application
    Filed: March 14, 2016
    Publication date: January 24, 2019
    Applicant: THE JOHNS HOPKINS UNIVERSITY
    Inventors: MARTIN G. POMPER, RONNIE C. MEASE, SANGEETA RAY
  • Patent number: 10156521
    Abstract: A detectable substrate for aldehyde dehydrogenase (ALDH) can be used for selecting cells that express ALDH. The detectable substrate can have a fluorescent moiety that has an excitation wavelength, an emission wavelength, or both, that does not overlap with the excitation wavelength, emission wavelength, or both, of green fluorescent protein.
    Type: Grant
    Filed: February 21, 2014
    Date of Patent: December 18, 2018
    Assignee: THE JOHNS HOPKINS UNIVERSITY
    Inventors: Martin G. Pomper, Haofan Wang, Il Minn, Steven D. Leach, Ronnie C. Mease
  • Publication number: 20180236112
    Abstract: The present invention provides bivalent and multivalent ligands with a view to improving the affinity and pharmacokinetic properties of a urea class of PSMA inhibitors. The compounds and their synthesis can be generalized to multivalent compounds of other target antigens. Because they present multiple copies of the pharmacophore, multivalent ligands can bind to receptors with high avidity and affinity, thereby serving as powerful inhibitors. The modular multivalent scaffolds of the present invention, in one or more embodiments, contains a lysine-based (?-, ?-) dialkyne residue for incorporating two or more antigen binding moieties, such as PSMA binding Lys-Glu urea moieties, exploiting click chemistry and one or more additional lysine residues for subsequent modification with an imaging and/or therapeutic nuclides or a cytotoxic ligands for tumor cell killing.
    Type: Application
    Filed: February 5, 2018
    Publication date: August 23, 2018
    Inventors: MARTIN G. POMPER, SANGEETA RAY, RONNIE C. MEASE, HASSAN SHALLAL
  • Publication number: 20180222922
    Abstract: Radiofluorinated 7-Amino-5-thio-thiazolo[4,5-d]pyrimidines targeting Fractalkine Receptor (CX3CR1) are disclosed. Methods of imaging CX3CR1-expressing tumors or cells also are disclosed.
    Type: Application
    Filed: June 8, 2016
    Publication date: August 9, 2018
    Applicant: THE JOHNS HOPKINS UNIVERSITY
    Inventors: MARTIN G. POMPER, RONNIE C. MEASE, XING YANG, CATHERINE FOSS
  • Patent number: 10039845
    Abstract: The prostate-specific membrane antigen (PSMA) is increasingly recognized as a viable target for imaging and therapy of cancer. Various 99mTc/Re-labeled compounds were prepared by attaching known Tc/Re chelating agents to an amino-functionalized PSMA inhibitor with or without a variable length linker moiety. Ex vivo biodistribution and in vivo imaging demonstrated the degree of specific binding to engineered PSMA+ PC3 PIP tumors.
    Type: Grant
    Filed: June 30, 2017
    Date of Patent: August 7, 2018
    Assignee: THE JOHNS HOPKINS UNIVERSITY
    Inventors: Martin G. Pomper, Sangeeta Ray, Ronnie C. Mease, Catherine Anne Foss
  • Publication number: 20180133348
    Abstract: Highly potent and selective radionuclide-based imaging and therapy agents targeting carbonic anhydrase IX with minimum non-specific organ uptake are disclosed. Methods of imaging and/or treating carbonic anhydrase IX-expressing cells or tumors also are disclosed.
    Type: Application
    Filed: June 1, 2016
    Publication date: May 17, 2018
    Inventors: XING YANG, IL MINN, STEVEN ROWE, SANGEETA RAY, RONNIE C. MEASE, MICHAEL GORIN, MOHAMAD ALLAF, MARTIN G. POMPER
  • Publication number: 20180085478
    Abstract: The prostate-specific membrane antigen (PSMA) is increasingly recognized as a viable target for imaging and therapy of cancer. Various 99mTc/Re-labeled compounds were prepared by attaching known Tc/Re chelating agents to an amino-functionalized PSMA inhibitor with or without a variable length linker moiety. Ex vivo biodistribution and in vivo imaging demonstrated the degree of specific binding to engineered PSMA+ PC3 PIP tumors.
    Type: Application
    Filed: June 30, 2017
    Publication date: March 29, 2018
    Applicant: THE JOHNS HOPKINS UNIVERSITY
    Inventors: MARTIN G. POMPER, SANGEETA RAY, RONNIE C. MEASE, CATHERINE ANNE FOSS
  • Publication number: 20180051039
    Abstract: PSMA-targeted PET/SPECT agents for imaging PSMA-positive cancer and or tumor neovasculature and PSMA-targeted radiotherapeutic agent for the treatment of PSMA-positive cancer or tumor neovasculature are disclosed. Methods of imaging PSMA expressing tumors, or cells and kits also are disclosed.
    Type: Application
    Filed: March 14, 2016
    Publication date: February 22, 2018
    Applicant: THE JOHNS HOPKINS UNIVERSITY
    Inventors: MARTIN G. POMPER, RONNIE C. MEASE, SANGEETA RAY
  • Patent number: 9884132
    Abstract: The present invention provides bivalent and multivalent ligands with a view to improving the affinity and pharmacokinetic properties of a urea class of PSMA inhibitors. The compounds and their synthesis can be generalized to multivalent compounds of other target antigens. Because they present multiple copies of the pharmacophore, multivalent ligands can bind to receptors with high avidity and affinity, thereby serving as powerful inhibitors. The modular multivalent scaffolds of the present invention, in one or more embodiments, contains a lysine-based (?, ?-) dialkyne residue for incorporating two or more antigen binding moieties, such as PSMA binding Lys-Glu urea moieties, exploiting click chemistry and one or more additional lysine residues for subsequent modification with an imaging and/or therapeutic nuclides or a cytotoxic ligands for tumor cell killing.
    Type: Grant
    Filed: September 8, 2016
    Date of Patent: February 6, 2018
    Assignee: THE JOHNS HOPKINS UNIVERSITY
    Inventors: Martin G. Pomper, Sangeeta Ray, Ronnie C. Mease, Hassan Shallal
  • Publication number: 20180009767
    Abstract: Compositions and methods for visualizing tissue under illumination with near-infrared radiation, including compounds comprising near-infrared, closed chain, sulfo-cyanine dyes and prostate specific membrane antigen ligands are disclosed.
    Type: Application
    Filed: June 9, 2017
    Publication date: January 11, 2018
    Applicants: THE JOHNS HOPKINS UNIVERSITY, INTUITIVE SURGICAL OPERATIONS, INC.
    Inventors: MARTIN G. POMPER, RONNIE C. MEASE, YING CHEN, SANGEETA RAY, JONATHAN SORGER
  • Publication number: 20170333576
    Abstract: Carbamate and beta-amino acid urea-based scaffolds that have high binding affinity to PSMA are disclosed. These scaffolds can be radiolabeled and used for imaging cells and tumors that express PSMA or for cancer radiotherapy. These compounds also can comprise a fluorescent dye and be used for imaging cells and tumors that express PSMA or for photodynamic therapy.
    Type: Application
    Filed: October 22, 2015
    Publication date: November 23, 2017
    Applicant: THE JOHNS HOPKINS UNIVERSITY
    Inventors: MARTIN G. POMPER, RONNIE C. MEASE, SANGEETA RAY, YING CHEN, XING YANG
  • Publication number: 20170283384
    Abstract: Compositions and methods for visualizing tissue under illumination with near-infrared radiation, including compounds comprising near-infrared, closed chain, sulfo-cyanine dyes and prostate specific membrane antigen ligands are disclosed.
    Type: Application
    Filed: June 9, 2017
    Publication date: October 5, 2017
    Applicants: THE JOHNS HOPKINS UNIVERSITY, INTUITIVE SURGICAL OPERATIONS, INC.
    Inventors: MARTIN G. POMPER, RONNIE C. MEASE, YING CHEN, SANGEETA RAY, JONATHAN SORGER
  • Patent number: 9776977
    Abstract: Prostate-specific membrane antigen (PSMA) targeting compounds are described. Uses of the compounds for imaging, therapy, cell sorting, and tumor mapping are also described.
    Type: Grant
    Filed: April 2, 2014
    Date of Patent: October 3, 2017
    Assignee: THE JOHNS HOPKINS UNIVERSITY
    Inventors: Martin G. Pomper, Ronnie C. Mease, Sangeeta Ray
  • Patent number: 9694091
    Abstract: The prostate-specific membrane antigen (PSMA) is increasingly recognized as a viable target for imaging and therapy of cancer. Various 99mTc/Re-labeled compounds were prepared by attaching known Tc/Re chelating agents to an amino-functionalized PSMA inhibitor with or without a variable length linker moiety. Ex vivo biodistribution and in vivo imaging demonstrated the degree of specific binding to engineered PSMA+PC3 PIP tumors.
    Type: Grant
    Filed: May 18, 2015
    Date of Patent: July 4, 2017
    Assignee: THE JOHNS HOPKINS UNIVERSITY
    Inventors: Martin G. Pomper, Sangeeta Ray, Ronnie C. Mease, Catherine Anne Foss
  • Publication number: 20170135961
    Abstract: The invention provides a nanoparticle composition that is decorated with a urea-based small-molecule peptidomimetic inhibitor of prostate specific membrane antigen (PSMA), which is expressed by almost all solid tumors. This strategy takes advantage of both the avidity of the functionalized nanoparticle for binding to PSMA and the ability of the nanoparticle to be retained for longer periods of time in the tumor due to enhanced leakage via EPR into the tumor interstitium and poor clearance due to underdeveloped or non-existent lymphatics within the tumor.
    Type: Application
    Filed: July 13, 2016
    Publication date: May 18, 2017
    Inventors: Sachin S. Chandran, Sangeeta Ray, Martin G. Pomper, Samuel R. Denmeade, Ronnie C. Mease
  • Publication number: 20170081298
    Abstract: Low-molecular weight gadolinium (Gd)-based MR contrast agents for PSMA-specific Ti-weighted MR imaging are disclosed. The (Gd)-based MR contrast agents exhibit high binding affinity for PSMA and exhibit specific Ti contrast enhancement at PSMA+ cells. The PSMA-targeted Gd-based MR contrast agents can be used for PSMA-targeted imaging in vivo. 86Y-labeled PSMA-binding ureas also are provided, wherein the PSMA-binding ureas also are suitable for use with other radiotherapeutics.
    Type: Application
    Filed: May 6, 2015
    Publication date: March 23, 2017
    Applicants: THE JOHNS HOPKINS UNIVERSITY, NORTHWESTERN UNIVERSITY
    Inventors: SANGEETA RAY, MARTIN G. POMPER, THOMAS J. MEADE, RONNIE C. MEASE, YING CHEN, XING YANG, MATTHEW ROTZ
  • Publication number: 20170049912
    Abstract: The present invention provides bivalent and multivalent ligands with a view to improving the affinity and pharmacokinetic properties of a urea class of PSMA inhibitors. The compounds and their synthesis can be generalized to multivalent compounds of other target antigens. Because they present multiple copies of the pharmacophore, multivalent ligands can bind to receptors with high avidity and affinity, thereby serving as powerful inhibitors. The modular multivalent scaffolds of the present invention, in one or more embodiments, contains a lysine-based (?, ?-) dialkyne residue for incorporating two or more antigen binding moieties, such as PSMA binding Lys-Glu urea moieties, exploiting click chemistry and one or more additional lysine residues for subsequent modification with an imaging and/or therapeutic nuclides or a cytotoxic ligands for tumor cell killing.
    Type: Application
    Filed: September 8, 2016
    Publication date: February 23, 2017
    Applicant: THE JOHNS HOPKINS UNIVERSITY
    Inventors: MARTIN G. POMPER, SANGEETA RAY, RONNIE C. MEASE, HASSAN SHALLAL
  • Patent number: 9422234
    Abstract: The invention provides a nanoparticle composition that is decorated with a urea-based small-molecule peptidomimetic inhibitor of prostate specific membrane antigen (PSMA), which is expressed by almost all solid tumors. This strategy takes advantage of both the avidity of the functionalized nanoparticle for binding to PSMA and the ability of the nanoparticle to be retained for longer periods of time in the tumor due to enhanced leakage via EPR into the tumor interstitium and poor clearance due to underdeveloped or non-existent lymphatics within the tumor.
    Type: Grant
    Filed: November 26, 2008
    Date of Patent: August 23, 2016
    Assignee: The Johns Hopkins University
    Inventors: Sachin S. Chandran, Sangeeta Ray, Martin G. Pomper, Samuel R. Denmeade, Ronnie C. Mease
  • Patent number: 9371360
    Abstract: The present invention provides bivalent and multivalent ligands with a view to improving the affinity and pharmacokinetic properties of a urea class of PSMA inhibitors. The compounds and their synthesis can be generalized to multivalent compounds of other target antigens. Because they present multiple copies of the pharmacophore, multivalent ligands can bind to receptors with high avidity and affinity, thereby serving as powerful inhibitors. The modular multivalent scaffolds of the present invention, in one or more embodiments, contains a lysine-based (?-, ?-)dialkyne residue for incorporating two or more antigen binding moieties, such as PSMA binding Lys-Glu urea moieties, exploiting click chemistry and one or more additional lysine residues for subsequent modification with an imaging and/or therapeutic nuclides or a cytotoxic ligands for tumor cell killing.
    Type: Grant
    Filed: November 30, 2012
    Date of Patent: June 21, 2016
    Assignee: THE JOHNS HOPKINS UNIVERSITY
    Inventors: Martin Gilbert Pomper, Sangeeta Ray, Ronnie C. Mease, Hassan Shallal
  • Publication number: 20160008493
    Abstract: A detectable substrate for aldehyde dehydrogenase (ALDH) can include a radiolabel. When acted upon by ALDH in an ALDH-expressing cell, e.g., cancer cells, the radiolabeled substrate accumulates in the ALDH-expressing cell. ALDH-expressing cells can be distinguished by the accumulated radioactivity. When combined with suitable imaging technique, the detectable substrate can be used for in vivo imaging of cancer cells.
    Type: Application
    Filed: March 17, 2014
    Publication date: January 14, 2016
    Applicant: THE JOHNS HOPKINS UNIVERSITY
    Inventors: MARTIN C. POMPER, HAOFAN WANG, IL MINN, RONNIE C. MEASE